Showing results (241-250 of 263) with videos related to
Sort By:
Pageof 27
Frontiers in Veterinary Science|April 2, 2020
Molecular Characterization of Haemaphysalis Species and a Molecular Genetic Key for the Identification of Haemaphysalis of North AmericaAlec T Thompson, Kristen Dominguez, Christopher A Cleveland, et al.Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.International Journal of Toxicology|June 3, 2022
Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and BenefitsCharles Mattis, Natalie Bratcher, Monika Burns, et al.Communications Chemistry|January 25, 2023
Spatial and temporal scales of variability for indoor air constituentsPascale S J Lakey, Youngbo Won, David Shaw, et al.The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.BMC Medicine|January 14, 2022
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infectionFeargal J Ryan, Christopher M Hope, Makutiro G Masavuli, et al.Annals of the Rheumatic Diseases|October 13, 2017
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiativeJasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, et al.Pageof 27